Islet Cell Antibodies at Diagnosis, But Not Leanness, Relate to a Better Cardiovascular Risk Factor Profile 5 Years After Diagnosis of NIDDM

Anders Gottsäter; Mubarik Ahmed; Bo Lilja; Per Fernlund; Göran Sundkvist

doi:10.2337/diacare.19.1.60

Short Reports

Islet Cell Antibodies at Diagnosis, But Not Leanness, Relate to a Better Cardiovascular Risk Factor Profile 5 Years After Diagnosis of NIDDM

Anders Gottsäter, PHD,
Mubarik Ahmed, MD,
Bo Lilja, PHD,
Per Fernlund, PHD and
Göran Sundkvist, PHD

Departments of Vascular and Renal Diseases, University of Lund, University Hospital MAS Malmo, Sweden
Departments of Endocrinology, University of Lund, University Hospital MAS Malmo, Sweden
Departments of Clinical Physiology, University of Lund, University Hospital MAS Malmo, Sweden
Departments of Clinical Chemistry, University of Lund, University Hospital MAS Malmo, Sweden

Address correspondence and reprint requests to Anders Gottsäter, PhD, Department of Vascular and Renal Diseases, University of Lund, University Hospital MAS, S-205 02 Malmö, Sweden

Diabetes Care 1996 Jan; 19(1): 60-63. https://doi.org/10.2337/diacare.19.1.60

Abstract

OBJECTIVE To evaluate the relationship between islet cell antibodies (ICAs) and the cardiovascular risk profile 5 years after clinical diagnosis of NIDDM.

RESEARCH DESIGN AND METHODS Five years after clinical diagnosis, we evaluated blood pressure (BP) and lipids in 17 NIDDM patients with ICA at diagnosis (age 60 ± 4 years) and 133 NIDDM patients without ICA at diagnosis (age 61 ± 1 year). Urinary albumin excretion was evaluated in a subset of 12 NIDDM patients with ICA at diagnosis (age 60 ± 4 years) and 82 NIDDM patients without ICA at diagnosis (age 61 ± 1 year).

RESULTS NIDDM patients without ICA showed higher BP (140/86 ± 2/1 mmHg vs. 128/79 ± 3/2 mmHg; P < 0.05), total cholesterol (6.10 ± 0.11 vs. 5.09 ± 0.29 mmol/l; P < 0.01), LDL-to-HDL ratio (3.85 ± 0.14 vs. 2.49 ± 0.18; P < 0.001), and triglycerides (2.58 ± 0.24 vs. 0.90 ± 0.06 mmol/l; P < 0.001), lower HDL cholesterol (1.08 ± 0.03 vs. 1.40 ± 0.08 mmol/l; P < 0.001), and higher urinary albumin excretion (0.16 ± 0.06 vs. 0.01 ± 0.01 g/24 h; P < 0.05) than NIDDM patients with ICA. Among NIDDM patients without ICA, no differences concerning BP or lipids were found between obese and nonobese patients.

CONCLUSIONS ICA at diagnosis of NIDDM is a marker of more favorable cardiovascular risk profile 5 years after clinical diagnosis.